Focus: Pharming Group is a publicly traded Dutch biotechnology company focused on biologics development, currently dependent on a single approved product (Leniolisib/JOENJA) for primary immunodeficiency disorders. The company operates as a specialized biotech with a concentrated revenue stream and active pipeline expansion in rare immune disorders.
Profile data last refreshed 4h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Pharming Group to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Pharming Group
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Pharming Group's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Company's sole approved NDA generating 100% of revenue; selective PI3K-delta inhibitor addressing rare genetic immunodeficiencies with significant clinical utility and orphan drug protections extending exclusivity to 2032.
High Growth Tech Stocks in Europe with Promising Potential - simplywall.st
High Growth Tech Stocks in Europe with Promising Potential simplywall.st
Top Cybin (HELP) Competitors 2026 - MarketBeat
Top Cybin (HELP) Competitors 2026 MarketBeat
FDA Accepts Pharming Group Application to Expand Joenja Use to Children Aged 4 to 11 - geneonline.com
FDA Accepts Pharming Group Application to Expand Joenja Use to Children Aged 4 to 11 geneonline.com
Pharming announces U.S. FDA acceptance of sNDA resubmission - GlobeNewswire
Pharming announces U.S. FDA acceptance of sNDA resubmission GlobeNewswire
Hereditary Angioedema Market to Reach USD 9.23 Billion by 2033 | - openPR.com
Hereditary Angioedema Market to Reach USD 9.23 Billion by 2033 | openPR.com
PHARM.AS Stock Price, Quote & Chart | PHARMING GROUP NV (AMS:PHARM) - ChartMill
PHARM.AS Stock Price, Quote & Chart | PHARMING GROUP NV (AMS:PHARM) ChartMill
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Natural history of clinical manifestations in activated phosphoinositide 3-kinase δ syndrome (APDS): Time-to-event analyses using the European Society for Immunodeficiencies-APDS registry.
Diagnostic odyssey of patients with the rare immunodeficiency activated PI3 kinase delta syndrome (APDS): case study from expert and patient surveys.
Showing 5 of 10 publications